Clavis Pharma appoints chief business officer

Nicholas Adams takes the role at Norwegian firm

Clavis Pharma, a Norwegian cancer drug development company, has appointed Nicholas Adams as chief business officer. He replaces Jan Alfheim, who has become managing director of Nordic Nanovector.

For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.

Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.

Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.

You may also like

Regulatory
Anticancer agent – elacytarabine

Anticancer agent – elacytarabine

Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Regulatory

Leukaemia treatment gains fast track designation

Clavis Pharma’s elacytarabine currently in Phase III trial
Research & Development
Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials
Research & Development
Rethinking the route to first-in-human studies

Rethinking the route to first-in-human studies

For sponsors, development activities and fragmented clinical supply can slow the path from candidate selection to first-in-human (FIH) dosing. A more integrated approach can reduce avoidable complexity while preserving the flexibility needed for early clinical programmes
Research & Development
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine

The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Research & Development
Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments
Manufacturing
Making blister package integrity testing decisions that QA can use

Making blister package integrity testing decisions that QA can use

A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions
Subscribe now